Antibodies

13 Dec 2019 Grifols launches XEMBIFY® (immune globulin subcutaneous human-klhw) 20%, a new Primary Immunodeficiency treatment
13 Dec 2019 Silverback Therapeutics Announces Preclinical Data at 2019 San Antonio Breast Cancer Symposium (SABCS) Supporting Development of SBT6050 as a Single Agent and in Combination with Trastuzumab for the Treatment of HER2-Expressing Malignancies
13 Dec 2019 Innate Pharma provides update on lacutamab TELLOMAK trial
13 Dec 2019 Genentech Announces Phase III Study Results for Tecentriq Plus Cotellic and Zelboraf in People With Previously Untreated BRAF V600 Mutation-positive Advanced Melanoma
13 Dec 2019 Data from Exploratory Analysis Show Merck’s KEYTRUDA® (pembrolizumab) Improved Overall Survival as Monotherapy for the First-Line Treatment of Metastatic Non-Small Cell Lung Cancer Regardless of KRAS Mutational Status
12 Dec 2019 Genentech’s Fixed-dose Subcutaneous Combination of Perjeta and Herceptin Comparable to Intravenous Formulations in People With HER2-positive Breast Cancer
12 Dec 2019 European Commission Approves EVENITY® (romosozumab) For The Treatment Of Severe Osteoporosis In Postmenopausal Women At High Risk Of Fracture
11 Dec 2019 Viela Bio Announces Initiation of Phase 2b Trial of VIB4920 in Sjögren’s Syndrome
11 Dec 2019 NeoImmuneTech Announces Clinical Collaboration to Evaluate Hyleukin-7™ (NT-I7) in Combination with KEYTRUDA® (pembrolizumab) in Patients with Advanced Solid Tumors
11 Dec 2019 Trastuzumab deruxtecan achieved a tumour response rate of 60.9% in pivotal Phase II HER2-positive metastatic breast cancer trial
11 Dec 2019 The Next Wave of Biosimilar Antibodies: new report analyzes competition in development of biosimilar antibodies for Lucentis, Eylea, Xolair, Prolia, Stelara, Soliris and More
11 Dec 2019 AffaMed Therapeutics Receives NMPA Approval to Initiate Phase III Clinical Trial in China with Herceptin® (Trastuzumab) Biosimilar Candidate AMT901
11 Dec 2019 Positive results presented from pivotal Phase 3 trial of sutimlimab in people with cold agglutinin disease
11 Dec 2019 Iterum Therapeutics Announces Topline Results from Phase 3 Clinical Trial of Oral and IV Sulopenem for the Treatment of Complicated Intra-abdominal Infections
11 Dec 2019 Regeneron and Sanofi Announce Intent to Restructure Antibody Collaboration for Kevzara® (sarilumab) and Praluent® (alirocumab)
11 Dec 2019 Darzalex (daratumumab) Regimen Shows Significant Increase in Progression-Free Survival in Treatment of Patients with Relapsed/Refractory Multiple Myeloma
11 Dec 2019 LEO Pharma announces positive top-line results for tralokinumab from three Phase 3 studies in adult patients with moderate-to-severe AD
11 Dec 2019 BioInvent and Transgene announce compelling preclinical data for BT-001 in solid tumors
11 Dec 2019 FDA Accepts Supplemental Biologics License Application for Xolair (Omalizumab) for the Treatment of Nasal Polyps
11 Dec 2019 First patient dosed in BIVV001 phase 3 XTEND-1 study in people with severe haemophilia A
10 Dec 2019 ADC Therapeutics Announces Oral Presentation of Interim Efficacy Data from Pivotal Phase 2 Clinical Trial of ADCT-402 (Loncastuximab Tesirine) in Patients with Relapsed or Refractory Diffuse Large B-Cell Lymphoma at 61st ASH Annual Meeting
10 Dec 2019 Forty Seven, Inc. Announces Foundational Preclinical Data Supporting the Development of FSI-174 in Combination with Magrolimab as a Novel All Antibody Conditioning Regimen for Hematopoietic Stem Cell Transplantation
10 Dec 2019 MacroGenics Presents Flotetuzumab Data in Patients with Primary Induction Failure and Early Relapsed Acute Myeloid Leukemia at the 2019 ASH Annual Meeting
10 Dec 2019 CARsgen Therapeutics Receives IND Clearance from the NMPA for AB011 Humanized Claudin18.2 Monoclonal Antibody
10 Dec 2019 CStone's anti-PD-L1 antibody demonstrates promising antitumor activity with a complete response rate of 33.3% and a good safety profile in patients with relapsed or refractory extranodal natural killer/T-cell lymphoma

La Merie Biologics

FREE Weekly News Bulletin

Sign Up

2019 Sales ofAntibodies & Proteins

New Product Alert

For La Merie Publishing

Sign Up

Top